JP2007527859A - グリコーゲンシンターゼキナーゼ−3阻害剤 - Google Patents
グリコーゲンシンターゼキナーゼ−3阻害剤 Download PDFInfo
- Publication number
- JP2007527859A JP2007527859A JP2006516816A JP2006516816A JP2007527859A JP 2007527859 A JP2007527859 A JP 2007527859A JP 2006516816 A JP2006516816 A JP 2006516816A JP 2006516816 A JP2006516816 A JP 2006516816A JP 2007527859 A JP2007527859 A JP 2007527859A
- Authority
- JP
- Japan
- Prior art keywords
- group
- amino
- acid
- gsk
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 **1cc(C*OP(O)(O)=O)c*(*)c1 Chemical compound **1cc(C*OP(O)(O)=O)c*(*)c1 0.000 description 7
- CHDFCCGMFONCRG-UHFFFAOYSA-N NCCc1cc(CCN)cc(COP(O)(O)=O)c1 Chemical compound NCCc1cc(CCN)cc(COP(O)(O)=O)c1 CHDFCCGMFONCRG-UHFFFAOYSA-N 0.000 description 1
- NTNYJUMYUPEXOP-UHFFFAOYSA-N NCCc1cc(CO)cc(CCN)c1 Chemical compound NCCc1cc(CO)cc(CCN)c1 NTNYJUMYUPEXOP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48271903P | 2003-06-27 | 2003-06-27 | |
US60/482,719 | 2003-06-27 | ||
US52849503P | 2003-12-11 | 2003-12-11 | |
US60/528,495 | 2003-12-11 | ||
PCT/IL2004/000570 WO2005000192A2 (en) | 2003-06-27 | 2004-06-27 | Glycogen synthase kinase-3 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2007527859A true JP2007527859A (ja) | 2007-10-04 |
Family
ID=33555590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006516816A Pending JP2007527859A (ja) | 2003-06-27 | 2004-06-27 | グリコーゲンシンターゼキナーゼ−3阻害剤 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1638557A4 (ko) |
JP (1) | JP2007527859A (ko) |
KR (1) | KR20060018902A (ko) |
CN (1) | CN1838954B (ko) |
CA (1) | CA2530111A1 (ko) |
WO (1) | WO2005000192A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008520649A (ja) * | 2004-11-18 | 2008-06-19 | テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. | グリコーゲンシンターゼキナーゼ−3阻害剤 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001049709A1 (en) | 2000-01-03 | 2001-07-12 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Glycogen synthase kinase-3 inhibitors |
US7378432B2 (en) | 2001-09-14 | 2008-05-27 | Tel Aviv University Future Technology Development L.P. | Glycogen synthase kinase-3 inhibitors |
EP1569956B1 (en) | 2002-12-12 | 2014-02-26 | Tel Aviv University Future Technology Development L.P. | Glycogen synthase kinase-3 inhibitors |
MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP2668199B1 (en) | 2011-01-27 | 2017-09-06 | Ramot at Tel Aviv University, Ltd. | Glycogen synthase kinase-3 inhibitors |
WO2012101601A1 (en) | 2011-01-27 | 2012-08-02 | Ramot At Tel-Aviv University Ltd. | Glycogen synthase kinase-3 inhibitors |
KR101668514B1 (ko) | 2011-02-25 | 2016-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체 |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
EP3013850B1 (en) | 2013-06-24 | 2018-07-25 | Ramot at Tel-Aviv University Ltd. | Glycogen synthase kinase-3 inhibitors |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB785457A (en) * | 1954-09-10 | 1957-10-30 | Ici Ltd | Phosphated metallisable azo dyestuffs |
JPS49125510A (ko) * | 1973-04-11 | 1974-12-02 | ||
JPS57212704A (en) * | 1981-06-24 | 1982-12-27 | Fujikura Ltd | Electric cable |
JPS5871937A (ja) * | 1981-10-23 | 1983-04-28 | Adeka Argus Chem Co Ltd | ハロゲン含有樹脂組成物 |
JPS63250063A (ja) * | 1987-04-03 | 1988-10-17 | Matsushita Electric Ind Co Ltd | 亜鉛アルカリ電池 |
WO2003008479A1 (fr) * | 2001-07-16 | 2003-01-30 | Teijin Limited | Catalyseur destine a la production de polyester et procede de production de polyester faisant intervenir ce catalyseur |
JP2006036784A (ja) * | 1998-09-04 | 2006-02-09 | Cell Signaling Technology Inc | 抗原としてペプチドライブラリーを用いたモチーフ特異性および状況独立性抗体の産生 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB781806A (en) * | 1955-04-29 | 1957-08-28 | Roche Products Ltd | Organic phosphate, salts thereof, and process for the manufacture thereof |
US6077954A (en) * | 1996-08-01 | 2000-06-20 | Isis Pharmaceuticals, Inc. | Substituted heterocyclic compounds |
WO2001049709A1 (en) * | 2000-01-03 | 2001-07-12 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Glycogen synthase kinase-3 inhibitors |
WO2002016318A1 (en) * | 2000-08-21 | 2002-02-28 | Pacific Corporation | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
-
2004
- 2004-06-27 WO PCT/IL2004/000570 patent/WO2005000192A2/en active Application Filing
- 2004-06-27 JP JP2006516816A patent/JP2007527859A/ja active Pending
- 2004-06-27 KR KR1020057025051A patent/KR20060018902A/ko not_active Application Discontinuation
- 2004-06-27 EP EP04744910A patent/EP1638557A4/en not_active Ceased
- 2004-06-27 CA CA002530111A patent/CA2530111A1/en not_active Abandoned
- 2004-06-27 CN CN2004800240175A patent/CN1838954B/zh not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB785457A (en) * | 1954-09-10 | 1957-10-30 | Ici Ltd | Phosphated metallisable azo dyestuffs |
JPS49125510A (ko) * | 1973-04-11 | 1974-12-02 | ||
JPS57212704A (en) * | 1981-06-24 | 1982-12-27 | Fujikura Ltd | Electric cable |
JPS5871937A (ja) * | 1981-10-23 | 1983-04-28 | Adeka Argus Chem Co Ltd | ハロゲン含有樹脂組成物 |
JPS63250063A (ja) * | 1987-04-03 | 1988-10-17 | Matsushita Electric Ind Co Ltd | 亜鉛アルカリ電池 |
JP2006036784A (ja) * | 1998-09-04 | 2006-02-09 | Cell Signaling Technology Inc | 抗原としてペプチドライブラリーを用いたモチーフ特異性および状況独立性抗体の産生 |
WO2003008479A1 (fr) * | 2001-07-16 | 2003-01-30 | Teijin Limited | Catalyseur destine a la production de polyester et procede de production de polyester faisant intervenir ce catalyseur |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008520649A (ja) * | 2004-11-18 | 2008-06-19 | テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. | グリコーゲンシンターゼキナーゼ−3阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
WO2005000192A2 (en) | 2005-01-06 |
KR20060018902A (ko) | 2006-03-02 |
EP1638557A4 (en) | 2007-11-07 |
WO2005000192A3 (en) | 2005-06-02 |
EP1638557A2 (en) | 2006-03-29 |
CN1838954B (zh) | 2013-01-16 |
CN1838954A (zh) | 2006-09-27 |
CA2530111A1 (en) | 2005-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7378432B2 (en) | Glycogen synthase kinase-3 inhibitors | |
JP2007527859A (ja) | グリコーゲンシンターゼキナーゼ−3阻害剤 | |
Martelli et al. | The emerging multiple roles of nuclear Akt | |
US7833974B2 (en) | Glycogen synthase kinase-3 inhibitors | |
US9243034B2 (en) | Glycogen synthase kinase-3 inhibitors | |
JP4954888B2 (ja) | グリコーゲンシンターゼキナーゼ−3阻害剤 | |
JP2002541065A5 (ko) | ||
WO2011160016A2 (en) | E3 binding pockets and identification and use of e3 ligase inhibitors | |
JP2003514850A (ja) | 薬剤を調製するためのインジルビン誘導体の使用 | |
US20040010045A1 (en) | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer | |
US9688719B2 (en) | Glycogen synthase kinase-3 inhibitors | |
WO2016017844A1 (ko) | 파골세포 분화 및 활성 억제능을 갖는 펩타이드 및 이의 용도 | |
US9718859B2 (en) | Glycogen synthase kinase-3 inhibitors | |
JP2007529540A (ja) | 混合系統キナーゼの阻害およびそのための用途 | |
JP2009502904A (ja) | 補体C3a由来のペプチド及びその使用 | |
JP2004018524A (ja) | 動脈硬化症を処置するための方法 | |
KR20030067161A (ko) | 다이하이드로 벤조퓨란구조를 골격으로 하는 카이네이즈저해 화합물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110301 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111004 |